“We decided as of last week to start developing a Soberana Plus variant having the Omicron RBD protein,” Verez said on Tuesday, referring to the receptor-binding domain (RBD), a key part of the virus located on its “spike”.
“We have already started it, and that protein is being built at the moment.”
In November, Verez said the Finlay Institute can produce 10 million Soberana doses per month, the journal Nature reported.
(...)
In developing Soberana-02, Verez’s institute drew on its existing conjugate vaccine technology. This involves taking a protein or sugar from a virus then chemically linking it to a harmless fragment of a neurotoxin protein from the tetanus bacterium, Nature reported.
“The combination elicits a stronger immune response than either component alone. Conjugate vaccines against meningitis and typhoid are used around the world, and Cuba has been immunizing children with a vaccine of this type for years,” according to data cited by the journal.
Cuba to update domestic vaccine to battle Omicron (AlJazeera, Dec 2, 2021)